{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:32:08Z","timestamp":1787002328450,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T00:00:00Z","timestamp":1472169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T00:00:00Z","timestamp":1472169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2016.75","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T09:22:35Z","timestamp":1472203355000},"page":"e463-e463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing"],"prefix":"10.1038","volume":"6","author":[{"given":"A","family":"Angona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Alvarez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Longar\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Pairet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Besses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Bellosillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,26]]},"reference":[{"key":"BFbcj201675_CR1","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","volume":"123","author":"M Cazzola","year":"2014","unstructured":"Cazzola M, Kralovics R . From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 2014; 123: 3714\u20133719.","journal-title":"Blood"},{"key":"BFbcj201675_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2141.2007.06755.x","volume":"139","author":"K Toyama","year":"2007","unstructured":"Toyama K, Karasawa M, Yamane A, Irisawa H, Yokohama A, Saitoh T et al. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Br J Haematol 2007; 139: 64\u201369.","journal-title":"Br J Haematol"},{"key":"BFbcj201675_CR3","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.2169\/internalmedicine.50.5429","volume":"50","author":"K Toyama","year":"2011","unstructured":"Toyama K, Karasawa M, Yokohama A, Mitsui T, Uchiumi H, Saitoh T et al. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr\/abl-negative chronic myeloproliferative neoplasm subtypes. Intern Med 2011; 50: 2557\u20132561.","journal-title":"Intern Med"},{"key":"BFbcj201675_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1600-0609.2006.00688.x","volume":"77","author":"PG Heller","year":"2006","unstructured":"Heller PG, Lev PR, Salim JP, Kornblihtt LI, Goette NP, Chazarreta CD et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol 2006; 77: 210\u2013216.","journal-title":"Eur J Haematol"},{"key":"BFbcj201675_CR5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945\u20131953.","journal-title":"Lancet"},{"key":"BFbcj201675_CR6","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/sj.leu.2404649","volume":"21","author":"B Bellosillo","year":"2007","unstructured":"Bellosillo B, Mart\u00ednez-Avil\u00e9s L, Gimeno E, Florensa L, Longar\u00f3n R, Navarro G et al. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. Leukemia 2007; 21: 1331\u20131332.","journal-title":"Leukemia"},{"key":"BFbcj201675_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","volume":"127","author":"JD Milosevic Feenstra","year":"2016","unstructured":"Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood 2016; 127: 325\u2013332.","journal-title":"Blood"},{"key":"BFbcj201675_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","volume":"127","author":"X Cabagnols","year":"2016","unstructured":"Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood 2016; 127: 333\u2013342.","journal-title":"Blood"},{"key":"BFbcj201675_CR9","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092\u20131097.","journal-title":"Blood"},{"key":"BFbcj201675_CR10","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","volume":"107","author":"RL Levine","year":"2006","unstructured":"Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139\u20134141.","journal-title":"Blood"},{"key":"BFbcj201675_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00277-011-1330-0","volume":"91","author":"L Mart\u00ednez-Avil\u00e9s","year":"2012","unstructured":"Mart\u00ednez-Avil\u00e9s L, Besses C, \u00c1lvarez-Larr\u00e1n A, Torres E, Serrano S, Bellosillo B . TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms. Ann Hematol 2012; 91: 533\u2013541.","journal-title":"Ann Hematol"},{"key":"BFbcj201675_CR12","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379\u20132390.","journal-title":"N Engl J Med"},{"key":"BFbcj201675_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","volume":"136","author":"TS Larsen","year":"2007","unstructured":"Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N . The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007; 136: 745\u2013751.","journal-title":"Br J Haematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201675.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201675","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201675.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T03:50:18Z","timestamp":1672804218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,26]]},"references-count":13,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8]]}},"alternative-id":["BFbcj201675"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2016.75","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,26]]},"assertion":[{"value":"26 August 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}